NNOX
Nano-X Imaging Ltd.
NNOX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over NNOX overall, supported by stronger fundamentals and lower modeled downside.
NNOX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
NNOX's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NNOX PE Valuation
NNOX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NNOX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NNOX's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NNOX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.70 | -$0.80 |
| Q1 2026 | -$1.14 | -$0.24 |
| Q4 2025 | -$1.15 | -$0.25 |
| Q3 2025 | -$0.88 | -$0.03 |
| Q2 2025 | -$0.90 | +$0.09 |
| Q1 2025 | -$0.90 | +$0.17 |
| Q4 2024 | -$0.90 | +$0.17 |
| Q3 2024 | -$0.85 | +$0.90 |
NNOX is still losing money, but less than at its worst: $1.70 per share over the past year, against $2.03 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NNOX on earnings quality, reporting a profit while its opponent remains loss making.
NNOX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.2M | +37% |
| Q1 2026 | $4.3M | +53% |
| Q4 2025 | $3.7M | +24% |
| Q3 2025 | $3.4M | +14% |
| Q2 2025 | $3M | +13% |
| Q1 2025 | $2.8M | +10% |
| Q4 2024 | $3M | +25% |
| Q3 2024 | $3M | +22% |
NNOX's revenue has grown year over year for 19 quarters in a row: $4M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1335% | -858 points |
| Q1 2026 | -343% | +157 points |
| Q4 2025 | -481% | +18 points |
| Q3 2025 | -413% | +54 points |
| Q2 2025 | -477% | +61 points |
| Q1 2025 | -501% | +12 points |
| Q4 2024 | -499% | +54 points |
| Q3 2024 | -466% | +421 points |
NNOX's operating margin was −1335% last quarter, down 858 points from the same quarter a year ago, near the bottom of its range since 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NNOX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NNOX on profitability, with a higher operating margin.
NNOX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.6M | -$2.2M |
| Q1 2026 | -$15.7M | -$4.9M |
| Q4 2025 | -$12.5M | -$922.8K |
| Q3 2025 | -$12.5M | -$3.6M |
| Q2 2025 | -$10.4M | -$1M |
| Q1 2025 | -$10.9M | -$1.3M |
| Q4 2024 | -$11.6M | +$890.5K |
| Q3 2024 | -$8.9M | +$3.5M |
NNOX has burned cash in almost every quarter: −$53M over the past year, against −$42M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NNOX on cash generation, producing positive trailing cash flow while its opponent burns cash.
NNOX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +312K shares |
| 1 year | +9.4% | +6M shares |
| 3 years | +26% | +14.6M shares |
| 5 years | +46% | +22.2M shares |
| Available history | +105% | +35.8M shares |
NNOX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NNOX hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NNOX Net Leverage
NNOX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NNOX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 7.0 | Oversold |
NNOX's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NNOX PE vs Healthcare Sector
NNOX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NNOX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.44 | 27% below |
| 20 week MA | $0.75 | 57% below |
| 50 week MA | $1.73 | 82% below |
| 100 week MA | $3.50 | 91% below |
| 200 week MA | $6.06 | 95% below |
NNOX is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NNOX on trend strength, trading above more of its moving averages.
NNOX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.6 | $52.5 | +5.7% |
| 2021 | $52.5 | $17.9 | -66% |
| 2022 | $17.9 | $8.02 | -55% |
| 2023 | $8.02 | $6.37 | -21% |
| 2024 | $6.37 | $7.59 | +19% |
| 2025 | $7.59 | $2.86 | -62% |
| 2026 YTD | $2.86 | $0.32 | -89% |
NNOX has finished lower in four of the last six years. It's down 89% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NNOX on returns for 2026, with the stronger performance.